论文部分内容阅读
目的探讨大剂量丙种球蛋白联合不同剂量阿司匹林治疗早期川崎病的临床疗效与安全性。方法选择东莞市康华医院2015年2月-2016年3月收治的72例早期川崎病患儿为研究对象,以随机数字表法分组,A组与B组各36例,A组行大剂量丙种球蛋白联合小剂量阿司匹林治疗,B组行大剂量丙种球蛋白联合大剂量阿司匹林治疗,对两组患儿疗效及安全性进行分析。结果 A组治疗总有效率为91.67%,B组为94.44%,两组差异无统计学意义(P>0.05);A组治疗后不良反应发生率为5.56%,与B组的33.33%相比,差异有统计学意义(P<0.05)。结论大剂量丙种球蛋白联合大、小剂量阿司匹林治疗早期川崎病均有满意疗效,但小剂量阿司匹林安全性更高,可作为首选用药方案。
Objective To investigate the clinical efficacy and safety of high-dose gamma globulin combined with different doses of aspirin in the treatment of early Kawasaki disease. Methods 72 patients with early Kawasaki disease admitted from February 2015 to March 2016 in the Kang Wah Hospital of Dongguan City were enrolled in this study. The patients were divided into three groups according to a random number table: 36 cases in group A and group B, Gamma globulin combined with low-dose aspirin treatment, B group high-dose gamma globulin combined with high-dose aspirin treatment, efficacy and safety of two groups were analyzed. Results The total effective rate of group A was 91.67%, while that of group B was 94.44%. There was no significant difference between the two groups (P> 0.05). The incidence of adverse reactions in group A was 5.56%, compared with 33.33% in group B , The difference was statistically significant (P <0.05). Conclusion High dose gamma globulin combined with large and small doses of aspirin in the treatment of early Kawasaki disease have a satisfactory effect, but the safety of small doses of aspirin is higher, as the preferred drug regimen.